Collectively, these results suggest a critical role for Mi-2β in regulating melanoma resistance to T-cell-meditated cytotoxicity with tumor-intrinsic Mi-2β levels regulating melanoma sensitivity to T-cell-mediated anti-tumor immunotherapy. The gene discussed is CHD4; the disease is melanoma.